Molecular Profile Detail

Profile Name CTNNB1 act mut
Gene Variant Detail

CTNNB1 act mut (gain of function)

Relevant Treatment Approaches CTNNB1 Inhibitor PDPK1 Inhibitor Tankyrase Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
CTNNB1 act mut sarcoma sensitive Imatinib Clinical Study Actionable In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 activating mutations demonstrated a greater progression arrest rate at 6 months compared to patients with CTNNB1 wild-type when treated with Gleevec (imatinib) (PMID: 26861905). 26861905
Clinical Trial Phase Therapies Title Recruitment Status